Profusa Presents Trial Results From Pilot Phase Study Of Peripheral Artery Disease Participants With Subcutaneous Hydrogel Sensors Implanted In The Arm And Foot

Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, January 28, 2026.  The study, conducted at the University of California San Francisco, San Francisco VA Medical Center, and San Francisco General Hospital, showed Lumee oxygen tissue monitoring is a safe and effective method for long term monitoring of peripheral artery disease (PAD) patients. The data also demonstrated strong correlation with traditional transcutaneous partial pressure of oxygen (tcpO2).

The presentation, titled, "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease," highlighted pilot phase study results from 15 PAD patients with subcutaneous hydrogel sensors implanted in the arm and foot. Tissue oxygenation was measured using both Lumee sensors and tcpO₂. Sensors were monitored over 12 months with visits at days 2, 10, 90, 180, and 365.